Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

actinium Ac 225-ABD147

A radioimmunoconjugate consisting of ABD147, an antibody fragment directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) conjugated with a linker-chelator to the alpha-emitting radioisotope actinium Ac 225 (225Ac), with potential antineoplastic activity. Upon administration of actinium Ac 225-ABD147, ABD147 targets and binds to DLL3 on DLL3-expressing tumor cells. Upon binding, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:225Ac-ABD147
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search